The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | BEAT-meso: Phase III trial of bevacizumab and chemo ± atezolizumab for advanced pleural mesothelioma
Melina Elpi Marmarelis, MD, University of Pennsylvania, Philadelphia, PA, discusses the BEAT-Meso trial (NCT03762018), an international Phase III study evaluating the efficacy and safety of adding atezolizumab to bevacizumab and chemotherapy in advanced pleural mesothelioma. The study showed that the addition of atezolizumab significantly increased progression-free survival (PFS) but did not significantly improve overall survival (OS). Notably, the combination of atezolizumab, bevacizumab and chemotherapy demonstrated superior outcomes in non-epithelioid cases. Grade ≥3 treatment-related adverse events were higher in the ABC arm compared to the BC arm. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Bluebird Bio; Gilead Sciences; Johnson & Johnson; Merck; Pfizer; Portola Pharmaceuticals
Honoraria – AstraZeneca; Blueprint Medicines; Blueprint Medicines; Health Advances (I); Janssen Oncology; Novocure; Takeda; Targeted Oncology; Thermo Fisher Scientific
Consulting or Advisory Role – AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Ikena Oncology
Research Funding – AstraZeneca (Inst); Lilly (Inst); Trizell (Inst)
Travel, Accommodations, Expenses – Boehringer Ingelheim; Novocure
